molibresib: Clinical Trials

7 trials of molibresib, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

2 completed, 2 terminated, 2 withdrawn, 1 no longer available. 5 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Terminated 2, Withdrawn 2, Completed 1
Phase 2	2	Completed 1, Withdrawn 1

Follow molibresib: new trials by email Literature Review of molibresib trials Research Report on molibresib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma Cisplatin, Etoposide, Etoposide Phosphate - Metastatic NUT Carcinoma, Unresectable NUT Carcinoma	Phase 1 / Phase 2	Withdrawn	National Cancer Institute (NCI)		2020-09-18	2020-09-28
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm	Phase 1	Withdrawn	National Cancer Institute (NCI)		2020-09-18	2020-09-28
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer GSK525762, Placebo, Fulvestrant - Neoplasms	Phase 1	Terminated	GlaxoSmithKline	124	2019-09-26	2024-08-29
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer GSK525762, Abiraterone, Enzalutamide - Solid Tumours	Phase 1	Terminated	GlaxoSmithKline	73	2017-07-18	2022-08-10
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies GSK525762 - Neoplasms	Phase 2	Completed	GlaxoSmithKline	111	2014-05-14	2024-10-01
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers GSK525762 - Carcinoma, Midline	Phase 1	Completed	GlaxoSmithKline	196	2012-03-28	2020-03-16
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma molibresib - Solid Tumours		No longer available	GlaxoSmithKline			2020-04-13

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding